Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics focuses on the research and development, industrialization and commercial expansion of antibody drugs in the fields of autoimmune and allergic diseases, and strives to solve the problems of drug accessibility and affordability. Based on the complete independent innovation capability, the company has formed a product pipeline of more than 10 innovative products, of which 7 products are in the clinical trial stage, covering psoriasis, atopic dermatitis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, asthma and other related diseases. Qyuns Therapeutics will keep the pace of filing 1-2 INDs each year, and continue to increase the pipeline value. At the same time, through the forward-looking layout of the production side and the sales side, the company continuously strengthens the certainty of development and strives to become a leading enterprise in the field of inflammatory diseases.